tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncowebtumors-166Research ArticleСтатьиМесто лучевой терапии в современном лечении лимфомы ХоджкинаДеминаЕлена Андреевна

г. Москва

drdemina@yandex.ruЛеонтьеваА. А.

г. Москва

РябухинаЮ. Е.

г. Москва

ТумянГ. С.

г. Москва

ТрофимоваО. П.

г. Москва

СотниковВ. М.

г. Москва

ЛарионоваВ. Б.

г. Москва

ПарамоноваЕ. В.

г. Москва

МанзюкЛ. В.

г. Москва

МухортоваО. В.

г. Москва

АсланидиИ. П.

г. Москва

ЗайцеваА. Ю.

г. Москва

РадкевичЛ. А.

г. Москва

РудасМ. С.

г. Москва

МануковаВ. А.

г. Москва

ОсмановЕ. А.

г. Москва

ФГБУ «РОНЦ им.Н.Н.Блохина» МЗ РФRussian FederationФГБУ РНЦРР МЗ РФRussian FederationФГБУ НЦССХ им.А.Н.Бакулева МЗ РФRussian FederationФГБУ «Клиническая больница № 1 УД Президента РФ»Russian FederationФГБУ «ЦКБ с поликлиникой УД Президента РФ»Russian Federation20152111201504s23943Copyright © Демина Е.А., Леонтьева А.А., Рябухина Ю.Е., Тумян Г.С., Трофимова О.П., Сотников В.М., Ларионова В.Б., Парамонова Е.В., Манзюк Л.В., Мухортова О.В., Асланиди И.П., Зайцева А.Ю., Радкевич Л.А., Рудас М.С., Манукова В.А., Османов Е.А., 20152015Демина Е.А., Леонтьева А.А., Рябухина Ю.Е., Тумян Г.С., Трофимова О.П., Сотников В.М., Ларионова В.Б., Парамонова Е.В., Манзюк Л.В., Мухортова О.В., Асланиди И.П., Зайцева А.Ю., Радкевич Л.А., Рудас М.С., Манукова В.А., Османов Е.А.Демина Е.А., Леонтьева А.А., Рябухина Ю.Е., Тумян Г.С., Трофимова О.П., Сотников В.М., Ларионова В.Б., Парамонова Е.В., Манзюк Л.В., Мухортова О.В., Асланиди И.П., Зайцева А.Ю., Радкевич Л.А., Рудас М.С., Манукова В.А., Османов Е.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/166

Лимфома Ходжкина (ЛХ) стала одним из первых заболеваний, при котором была доказана возможность излечения: 10–20-летняя выживаемость без прогрессирования (ВБП) 70–90%. Однако поздние осложнения лечения (вторые опухоли, инфаркты миокарда, инфекции) существенно снижают общую выживаемость. Молодой возраст больных и прогноз на столь же долгую жизнь, как и у сверстников, делают актуальным сохранение высокого качества дальнейшей жизни. Повышенный риск тяжелых осложнений дал импульс к поиску новых вариантов лечения ЛХ высокоэффективных и малотоксичных. Инструментом для достижения такой цели стала позитронно-эмиссионная томография (ПЭТ) – больные с негативными результатами ПЭТ имеют лучший прогноз. В настоящее время изучается возможность адаптации терапии по результатам ПЭТ после проведения 2–3 циклов полихимиотерапии. Для оценки эффективности терапии ПЭТ выполнена 61 больному с распространенными стадиями ЛХ, которым проводилось лечение 6 циклами ЕАСОРР-14+лучевая терапия в ФГБУ «РОНЦ им.Н.Н.Блохина» МЗ РФ. 4-летняя ВБП была лучше при негативной ПЭТ (52 больных), чем при позитивной (9 больных) и составила 93,8% против 44,4%, р=0,002. ПЭТ-2 выполнена у 36 больных, 4-летняя ВБП составила 100% при ПЭТ- и 81,8% при ПЭТ+, р=0,032. Консолидирующая лучевая терапия выполнена у 65 больных и у 18 больных не проводилась, рецидив констатирован у 1 больного в каждой группе и различия в ВБП выявлено не было: 4-летняя ВБП 93,3% против 88,9%, соответственно, р=0.177. Небольшая численность групп, позволяет сделать лишь предварительные выводы о прогностической значимости ПЭТ-2 и ПЭТ после этапа химиотерапии для коррекции программы лечения.

лимфома Ходжкиналучевая терапияПЭТReferencesPussey W. A. Cases of sarcoma and of Hodgkin’s disease treated by exposures to X-rays: preliminary report. JAMA. 1902; 98: 166–169.Pussey W. A. Cases of sarcoma and of Hodgkin’s disease treated by exposures to X-rays: preliminary report. JAMA. 1902; 98: 166–169.Gilbert R. La roengentherapie de la granulematise maligne. J. Radiol. Electrol. 1925; 9: 509–514.Gilbert R. La roengentherapie de la granulematise maligne. J. Radiol. Electrol. 1925; 9: 509–514.Peters M. A study in survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol. 1950;63:299–311.Peters M. A study in survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol. 1950;63:299–311.Kaplan H. The radical radiotherapy of Hodgkin’s disease. Radiology. 1962;78:553–61.Kaplan H. The radical radiotherapy of Hodgkin’s disease. Radiology. 1962;78:553–61.Hoppe R. T., Hanlon A., Hanks G. et al. Progress in treatment of Hodgkin`s disease in the United States, 1973 versus 1983: the patterns of care study. Cancer 1994; 74: 3198–203.Hoppe R. T., Hanlon A., Hanks G. et al. Progress in treatment of Hodgkin`s disease in the United States, 1973 versus 1983: the patterns of care study. Cancer 1994; 74: 3198–203.Hoppe R. T. Radiation therapy in the management of Hodgkin`s disease. Semin. Oncol. 1990; 17(6): 704–15.Hoppe R. T. Radiation therapy in the management of Hodgkin`s disease. Semin. Oncol. 1990; 17(6): 704–15.DeVita Jr V. T., Carbone P. P. Treatment of Hodgkin’s disease. Med Ann Dist Columbia. 1967; 36(4): 232–4.DeVita Jr V. T., Carbone P. P. Treatment of Hodgkin’s disease. Med Ann Dist Columbia. 1967; 36(4): 232–4.DeVita V.T., Serpick A. A., et al. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970; 73(6): 881–95.DeVita V.T., Serpick A. A., et al. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970; 73(6): 881–95.Bonadonna G., Valagussa P., Santoro A. Alternating noncross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986; 104: 739–46.Bonadonna G., Valagussa P., Santoro A. Alternating noncross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986; 104: 739–46.Prosnitz L. R., Farber L. R., Fisher J. J. et al. Long term remissions with combined modality therapy for advanced Hodgkin’s disease. Cancer 1976; 37: 2826–33.Prosnitz L. R., Farber L. R., Fisher J. J. et al. Long term remissions with combined modality therapy for advanced Hodgkin’s disease. Cancer 1976; 37: 2826–33.Girinsky T, van der Maazen R, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270–7.Girinsky T, van der Maazen R, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270–7.Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early stage Hodgkin’s disease. N Engl J Med. 2007;357: 1916–27.Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early stage Hodgkin’s disease. N Engl J Med. 2007;357: 1916–27.Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25:3495–502.Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25:3495–502.Borchmann P, Dieh V, Goergen H, et al. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 trial [abstract]. Blood. 2009;114:299–300.Borchmann P, Dieh V, Goergen H, et al. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 trial [abstract]. Blood. 2009;114:299–300.Thomas J, Ferme C, Noordijk E, et al. Results of the EORTCGELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma [abstract]. Haematologica. 2007; 92: 27.Thomas J, Ferme C, Noordijk E, et al. Results of the EORTCGELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma [abstract]. Haematologica. 2007; 92: 27.Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited- stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 4634–42.Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited- stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 4634–42.Diehl V, H. H, Mueller RP, Eich HT, Mueller-Hermelink H, Cerny T, et al. Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Or without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG). Blood (ASH Annual Meeting Abstracts). 2008; Abstract 1558.Diehl V, H. H, Mueller RP, Eich HT, Mueller-Hermelink H, Cerny T, et al. Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Or without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG). Blood (ASH Annual Meeting Abstracts). 2008; Abstract 1558.Hodgson DС, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol.2007;25:1489–97.Hodgson DС, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol.2007;25:1489–97.Myrehaug S, Pintilie M, Yun L, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010; 116 (13): 2237–2240.Myrehaug S, Pintilie M, Yun L, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010; 116 (13): 2237–2240.Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin lymphoma. N Engl J Med 2010; 363: 640–652.Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin lymphoma. N Engl J Med 2010; 363: 640–652.Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012; 366: 399–408.Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012; 366: 399–408.Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial. ASH Annual Meeting Abstracts 2012; 120: 547.Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial. ASH Annual Meeting Abstracts 2012; 120: 547.Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32: 1188–1194.Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32: 1188–1194.Andrieu JM, Yilmaz U, Colonna P. MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin’s disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. J Clin Oncol. 1999; 17: 730–4.Andrieu JM, Yilmaz U, Colonna P. MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin’s disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. J Clin Oncol. 1999; 17: 730–4.Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol. 1998;16:818–29.Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol. 1998;16:818–29.ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6): vi55–8.ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6): vi55–8.Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van ‘t Veer MB, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003; 348:2396–406.Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van ‘t Veer MB, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003; 348:2396–406.Ferme C et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006; 107: 4636–42.Ferme C et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006; 107: 4636–42.de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol. 2001; 12: 29–37.de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol. 2001; 12: 29–37.Spaepen K, Stroobants S, Dont P, et al. Can positron emission tomography with [(18F)]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272–278.Spaepen K, Stroobants S, Dont P, et al. Can positron emission tomography with [(18F)]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272–278.Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18Ffluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin’s disease. Blood. 2001; 98: 2930–2934.Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18Ffluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin’s disease. Blood. 2001; 98: 2930–2934.Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Blood. 2008; 112: 3989–3994.Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Blood. 2008; 112: 3989–3994.Markova J, Kahraman D, Kobe, et al. Role of [18F]-fluoro-2-deoxy- D -glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & Lymphoma, January 2012; 53(1): 64–70.Markova J, Kahraman D, Kobe, et al. Role of [18F]-fluoro-2-deoxy- D -glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & Lymphoma, January 2012; 53(1): 64–70.Engert A, Haverkamp H, Kobe C, Markova J, et al. Reducedintensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379(9828): 1791–9.Engert A, Haverkamp H, Kobe C, Markova J, et al. Reducedintensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379(9828): 1791–9.Magagnoli M., Marzo K, Balzarotti M1 et al, Dimension of Residual CT Scan Mass in Hodgkin’s Lymphoma (HL) Is a Negative Prognostic Faktor in Patients with PET Negative After Chemo+/-Radiotherapy. Blood (ASH Annual Meeting Abstracts) 2011 118: Abstract 93.Magagnoli M., Marzo K, Balzarotti M1 et al, Dimension of Residual CT Scan Mass in Hodgkin’s Lymphoma (HL) Is a Negative Prognostic Faktor in Patients with PET Negative After Chemo+/-Radiotherapy. Blood (ASH Annual Meeting Abstracts) 2011 118: Abstract 93.Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positronemission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian- Danish study. J Clin Oncol. 2007; 25: 3746–3752.Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positronemission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian- Danish study. J Clin Oncol. 2007; 25: 3746–3752.

The authors declare that there are no conflicts of interest present.